Decreased pre-surgical CD34+/CD144+ cell number in patients undergoing coronary artery bypass grafting compared to coronary artery disease-free valvular patients

Redondo, Santiago; Rocafort, Álvaro González; Navarro‐Dorado, Jorge; Ramajo, Marta; Hristov, Mihail; Gordillo‐Moscoso, Antonio; Reguillo, Fernando del Rey; Carnero, Manuel; Martı́nez-González, José; Rodrı́guez, Enrique; Weber, Christian; Tejerina, Teresa

doi:10.1186/1749-8090-7-2

Cited by 4 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are in line with the study by Redondo et al that reported elevated CD34+kdr+ cell level in patients with severe AS before AVR compared to a control group. [ 18 ]…”

Section: Discussionmentioning

confidence: 99%

“…Several clinical studies that included a low number of patients, showed contradictory results with regard to circulating EPCs in patients with significant AS. [ 16 – 18 ] The aim of this study was to assess circulating EPC numbers in a larger cohort of patients with AS and to study for the first time, the predictive value of circulating EPC levels on prognosis in these patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Endothelial Progenitor Cells and Clinical Outcome in Patients with Aortic Stenosis

et al. 2016

View full text Add to dashboard Cite

BackgroundAortic stenosis (AS) is the most common valvular disease. Endothelial progenitor cells (EPCs) have a role in the repair of endothelial surfaces after injury. Reduced numbers of EPCs are associated with endothelial dysfunction and adverse clinical events, suggesting that endothelial injury in the absence of sufficient repair by circulating EPCs promotes the progression of vascular and possibly valvular disorders. The aim of this study was to assess EPC number in patients with AS and to study the predictive value of their circulating levels on prognosis.MethodsThe number of EPCs was determined by flow cytometry in 241 patients with AS and a control group of 73 pts. Thirty-eight, 52 and 151 patients had mild, moderate and severe AS, respectively. We evaluated the association between baseline levels of EPCs and death from cardiovascular causes during follow up.ResultsEPC level was significantly higher in patients with AS compared to the control group (p = 0.017). Two hundred and three patients with moderate and severe AS were followed for a median of 20 months. One hundred and twenty patients underwent an intervention. Thirty four patients died during follow up, 20 patients died due to cardiac causes. Advanced age, the presence of coronary artery disease, AS severity index (combination of high NYHA class, smaller aortic valve area and elevated pulmonary artery pressure) and a low EPC number were predictors of cardiac death in the univariate analysis. Multivariate logistic regression model identified low EPCs number and AS severity index as associated with cardiac death during follow up (p = 0.026 and p = 0.037, respectively).ConclusionsEPC number is increased in patients with AS. However, in patients with moderate or severe AS a relatively low number of EPCs is associated with cardiac death at follow up. These results may help to identify AS patients at increased cardiovascular risk.

show abstract

“…Our results are in line with the study by Redondo et al that reported elevated CD34+kdr+ cell level in patients with severe AS before AVR compared to a control group. [ 18 ]…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Circulating Endothelial Progenitor Cells and Clinical Outcome in Patients with Aortic Stenosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For the diagnosis, levels of entothelial progenitor cells could increase as a response to ischemia, being low in healthy patients, high in ischemic patients and suboptimal in atherosclerotic patients. This was the case, for example, in cardiac surgery patients, having valvular patients increased levels of CD34+/CD144+ progenitors compared to healthy controls, whereas coronary artery bypass grafting patients yielded intermediate numbers, what suggested suboptimal mobilization [9]. This impaired mobilization could also explain the link between a decreased number of these cells during exercise and subsequent cardiovascular risk [10].…”

Section: The First Challenge: From Endothelial Progenitor Cells To a ...mentioning

confidence: 99%

The Journey to Clonal Hematopoiesis and Applications Incardiovascular Disease and Cancer

Redondo,

Perez de Oteyza

2023

Preprint

View full text Add to dashboard Cite

: For a long time, atherosclerosis has been regarded as a mere lipid deposit in the blood vessels. However, in the recent years a growing body of experimental and clinical evidence have highlighted the role of inflammation and immunity as a central mechanism of disease. Moreover, in the last decade the coming of next-generation sequencing and its application to large human population has broken the barrier between inflammation and cancer. Indeed, acquired mutation in key genes related to the control of hematopoiesis and myeloproliferation have paved the way to establish the new concept of clonal hematopoiesis of indeterminate potential. This phenomenon is being considered not such “indeterminate”, but as an emerging cardiovascular risk factor. Thus, this may explain the mechanisms of myeloproliferation and inflammation in atherosclerosis. And in a bidirectional journey, it has helped to explain the extremely high cardiovascular risk in cancer survivors, in particular in myeloprolfierative neoplasm patients. A deeper understanding of these mechanisms may pave the way for the future early diagnosis and potential preemptive treatments of the leading worldwide cause of death.

show abstract

“…A decellularised cryopreserved pulmonary allograft was seeded with autologous vascular ECs isolated from patient's forearm vein to create a viable TEHV; the right ventricular outflow tract was successfully reconstructed after Ross procedure (Ref. EPCs are supposed to be recruited towards cardiac tissue in patients with coronal problems such as aortic valve regurgitation, dysfunctional congenitally-bicuspid aortic valves, aortic valve stenosis, or after coronary artery bypass grafting ( Refs 181,182,183,184,185). EPCs express endothelial markers such as CD31, VE-Cadherin and endothelial nitric oxide synthase (eNOS); and after seeding they also express α smooth muscle (αSM) actin, matrix metalloproteinase 2 (MMP2)/9 and metalloproteinase inhibitors ( Refs 186,187).…”

Section: Adult Stem Cellsmentioning

confidence: 99%

“…180). EPCs are supposed to be recruited towards cardiac tissue in patients with coronal problems such as aortic valve regurgitation, dysfunctional congenitally-bicuspid aortic valves, aortic valve stenosis, or after coronary artery bypass grafting (Refs 181, 182, 183, 184, 185). EPCs express endothelial markers such as CD31, VE-Cadherin and endothelial nitric oxide synthase (eNOS); and after seeding they also express α smooth muscle (αSM) actin, matrix metalloproteinase 2 (MMP2)/9 and metalloproteinase inhibitors (Refs 186, 187).…”

Section: Tehvsmentioning

confidence: 99%

Heart valve tissue engineering: how far is the bedside from the bench?

Sanz-García

Cruz

Mirabet³

et al. 2015

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Heart disease, including valve pathologies, is the leading cause of death worldwide. Despite the progress made thanks to improving transplantation techniques, a perfect valve substitute has not yet been developed: once a diseased valve is replaced with current technologies, the newly implanted valve still needs to be changed some time in the future. This situation is particularly dramatic in the case of children and young adults, because of the necessity of valve growth during the patient's life. Our review focuses on the current status of heart valve (HV) therapy and the challenges that must be solved in the development of new approaches based on tissue engineering. Scientists and physicians have proposed tissue-engineered heart valves (TEHVs) as the most promising solution for HV replacement, especially given that they can help to avoid thrombosis, structural deterioration and xenoinfections. Lastly, TEHVs might also serve as a model for studying human valve development and pathologies.

show abstract

Decreased pre-surgical CD34+/CD144+ cell number in patients undergoing coronary artery bypass grafting compared to coronary artery disease-free valvular patients

Cited by 4 publications

References 23 publications

Circulating Endothelial Progenitor Cells and Clinical Outcome in Patients with Aortic Stenosis

Circulating Endothelial Progenitor Cells and Clinical Outcome in Patients with Aortic Stenosis

The Journey to Clonal Hematopoiesis and Applications Incardiovascular Disease and Cancer

Heart valve tissue engineering: how far is the bedside from the bench?

Contact Info

Product

Resources

About